Active with AF Finding the right balance

Created 10/16/2015 Dr. Matthew Fay: Westcliffe Medical Group

Dr Matthew Fay GP Principal The Willows Medical Practice:-Queensbury

GPwSI and Co-Founder Westcliffe Cardiology Service

Clinical Partner The Westcliffe Medical Group

Declaration of interests

• The practice has received funding from: Abbott, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Dawn, INRStar, Medtronic, Oberoi Consulting, Pfizer, Roche, Sanofi-Aventis, Servier.

• An advisor to: AF Association, Anticoagulation Europe, Arrhythmia Alliance, Heart Valve Voice, National Stroke Association, Syncope Trust

• A trustee of Thrombosis UK

Dabigat ran etexilate for the

prevent ion of st roke and systemic

embolism in at rial f ibrillat ion

Issued: March 2012

NICE technology appraisal guidance 249

guidance.nice.org.uk/ta249

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and

applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to

the methods of technology appraisal' (2008). More information on accreditation can be viewed at

www.nice.org.uk/accreditation

© NICE 2012

Rivaroxaban for the prevent ion of

st roke and systemic embolism in

people with at rial f ibrillat ion

Issued: May 2012

NICE technology appraisal guidance 256

guidance.nice.org.uk/ta256

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and

applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to

the methods of technology appraisal' (2008). More information on accreditation can be viewed at

www.nice.org.uk/accreditation

© NICE 2012

Apixaban for prevent ing st roke and

systemic embolism in people with

nonvalvular at rial f ibrillat ion

Issued: February 2013

NICE technology appraisal guidance 275

guidance.nice.org.uk/ta275

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and

applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to

the methods of technology appraisal' (2008). More information on accreditation can be viewed at

www.nice.org.uk/accreditation

© NICE 2013

Atrial f ibrillat ion: the management

of at rial f ibrillat ion

Issued: June 2014

NICE clinical guideline 180

guidance.nice.org.uk/cg180

NICE has accredited the process used by the Centre for Clinical Practice at NICE to produce

guidelines. Accreditation is valid for 5 years from September 2009 and applies to guidelines produced

since April 2007 using the processes described in NICE's 'The guidelines manual' (2007, updated

2009). More information on accreditation can be viewed at www.nice.org.uk/accreditation

© NICE 2014

NICE

Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of

thrombophilia testing

June 2012

Deep vein thrombosis

Atrial f ibrillat ion: t reatment and

management

Issued: July 2015

NICE quality standard 93

guidance.nice.org.uk/qs93

© NICE 2015

NICE Quality Standard 93

Statement 1

• Adults with non-valvular atrial fibrillation and a CHA2DS2-VASc stroke risk score of 2 or above are offered anticoagulation

NICE Quality Standard 93

Statement 2

• Adults with atrial fibrillation are not prescribed aspirin monotherapy for stroke prevention

NICE Quality Standard 93

Statement 3

• Adults with atrial fibrillation who are prescribed anticoagulation discuss the options with their healthcare professional at least once a year.

NICE Quality Standard 93

Statement 4

• Adults with atrial fibrillation taking a vitamin K antagonist who have poor anticoagulation control have their anticoagulation reassessed

NICE Quality Standard 93

Statement 6 (Developmental)

• Adults with atrial fibrillation on long term vitamin K antagonist therapy are supported to self-manage with a coagulometer

NICE Quality Standard 93

Statement 5

• Adults with atrial fibrillation whose treatment

Diet

Coffee

Activity

Sleep

Exercise

Travel

Sex

Medication

Anticoagulation

Anticoagulation

Warfarin

Anticoagulation

Not Warfarin

Thank you for your attention

matthew.fay@bradford.nhs.uk

@fatherofhan